MADISON, Wis.--(BUSINESS WIRE)--Promega Corporation announces the launch of the Maxwell® CSC Instrument and integrated reagent kits for Blood DNA and DNA FFPE. These new solutions, now available in the U.S., have been developed and manufactured in compliance with FDA’s Quality System Regulation and are intended for use as In Vitro Diagnostic (IVD) medical devices. Complying with these stringent requirements ensures consistent performance between instruments and runs.
The Maxwell technology extracts nucleic acid using novel paramagnetic particles which allows optimal capture, wash and elution of the target material. Because there are no tubes or pipette tips involved, there are no clogs, drips, splashing or aerosols, greatly reducing any contamination risk. Depending on which specific Maxwell CSC kits are used (for Blood or FFPE tissues), the instrument can purify DNA from up to 16 samples in under 45 minutes of processing time, providing high quality nucleic acids appropriate for downstream analysis in amplification-based assays.
The Maxwell CSC system’s Windows® 7-based touchscreen interface provides laboratories the ability to easily track samples, instrument self-check reports, kit lot number and expiration dates, operator usage, and to document parameters and protocols.
The Maxwell CSC is the next-generation, bench-top automation system for rapid nucleic acid isolation. It offers clinical customers and partners a high-quality, cGMP-compliant alternative to their current extraction methods.
See www.promega.com/maxwellcsc for more information.
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.